Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 20Lung Neoplasms 18Glioma 13Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Multiple Myeloma 10Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Mouth Neoplasms 9Colorectal Neoplasms 8Carcinoma, Renal Cell 8Ovarian Neoplasms 7Oropharyngeal Neoplasms 7Melanoma 7Laryngeal Neoplasms 7Glioblastoma 7Carcinoma, Hepatocellular 7Carcinoma 7Wilms Tumor 6Sarcoma 6Neuroblastoma 6Nasopharyngeal Carcinoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Fallopian Tube Neoplasms 6Triple Negative Breast Neoplasms 5Rhabdoid Tumor 5

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2sargramostim 1montanide ISA 51 1incomplete Freund's adjuvant 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Phantoms, Imaging 1Methods 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡